Pacific Edge plans to open its first US franchise to market the company’s bladder cancer detection test, Cxbladder, to urologists in the United States by the end of the year.
The Dunedin-based firm will set up shop at the Hershey Center for Applied Research (HCAR) on America’s East Coast.
The 11,348 square-foot Pacific Edge facility will serve as an office and processing facility for the analysis of the Cxbladder test – which utilises the expression of genes in the patients’ urine to detect the presence of bladder cancer accurately and non-invasively.
Planning and construction for the new facility is currently underway and will involve about 100 new employees over the next three year.
“It’s a huge opportunity to be in the US market,” says David Darling, CEO of Pacific Edge, “It’s probably the biggest prize in the world when it comes to a responsive healthcare market that really understands what molecular diagnostics can do in a clinical setting.”
Pacific Edge has been scoping potential marketing opportunities for some time.
“As part of our business development process we met the people from HCAR in Europe at a business partnering forum, where we were looking for opportunities and various reasons in the United States to see where we should be best located strategically,” Mr Darling says.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- TPP: Hope turns to delay in Atlanta
- Loan shark sentenced to fine and banned from lending
- Editor’s Insight: More hope for science or just extra pie in the sky?
- Government science plan seeks to double private sector R&D by 2025
- NZ Super's Fiona Mackenzie ranks high on global sovereign wealth fund list